Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11471417 Deuterated N,N-dimethyltryptamine compounds

Patent 11471417 was granted and assigned to Small Pharma Ltd on October, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11471417

Date of Patent

October 18, 2022

Patent Application Number

17458167

Date Filed

August 26, 2021

Patent Citations

‌

US Patent 11000534 Deuterated derivatives of psilocybin and uses thereof

Patent Citations Received

‌

US Patent 12110272 Deuterated tryptamine derivatives and methods of use

‌

US Patent 11958807 Deuterated tryptamine derivatives and methods of use

‌

US Patent 12076311 Therapeutic compositions comprising deuterated or partially deuterated N,N-dimethyltryptamine compounds

‌

US Patent 12084417 Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses

‌

US Patent 11746088 Deuterated tryptamine derivatives and methods of use

‌

US Patent 11834410 Deuterated tryptamine derivatives and methods of use

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11471417 Deuterated N,N-dimethyltryptamine compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API